Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro
Palabras clave : 
Improved OS
Docetaxel
Fecha de publicación : 
2018
Editorial : 
Elsevier
ISSN : 
0923-7534
Cita: 
Herbst, R.S. (Roy S.); Garon, E.B. (E. B.); Kim, D.W, (D. W.); et al. "Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro". Annals of oncology. 29 (Supl. 10), 2018, 42
Resumen
In the global, open-label, phase 2/3 study KEYNOTE-010, pembro 10 mg/kg or 2 mg/kg Q3W improved OS vs docetaxel in pts with previously treated advanced NSCLC with PD-L1 TPS ≥50% and ≥1% (coprimary analyses) at median follow-up of 13.1 mo. We present long-term results overall, in pts who completed 35 cycles (∼2 y) of pembro, and in pts who received a second course of pembro.

Ficheros en este ítem:
Vista previa
Fichero
PIIS0923753419327607.pdf
Descripción
Tamaño
88.94 kB
Formato
Adobe PDF


Estadísticas e impacto
0 citas en
0 citas en

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.